Genscript Biotech (HKG:1548) expects an increase in net profit in 2024, compared with the corresponding period of the previous year, according to a Sunday filing with the Hong Kong Bourse.
The company attributed the increased net profit to a one-time, tax-free unrealized gain of $3.2 billion from Legend Biotech's deconsolidation and future revenue from Probio's sublicensing, despite a $124 million fair value loss.
The life science research business plans to publish its annual results by the end of March.
The company's shares were down over 2% in the recent trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.